Main Article Content
methylcellulose K4M (HPMC) as hydrophilic gel material, sodium bicarbonate as gas-generating agent and Citric Acid as floating assistant agent. A 32 factorial design was used to select the optimized formulation wherein HPMC K4M (X1) and
Citric Acid (X2) were taken as independent variables and Floating lag time (FLT), amount of drug release after 24hrs. (Q24) were taken as dependent variables. The release data were evaluated by the model-dependent (curve fitting) method using PCP Disso v2.08 software. Optimisation studies were carried out by using the Design Expert software (version 8.0.1). The floating tablets were evaluated for uniformity of weight, hardness, thickness, swelling index, friability, drug content, FLT, and in vitro release. The in vitro drug release followed Hixson-Crowell model and mechanism of drug release was found to be anomalous or non-fickian type. The optimized formulation was F3 containing HPMC K4M 15%, and Citric acid 3% having minimum FLT and maximum drug release after 24 hrs.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Abrahamsson B, Alpsten M, Hugosson M, Jonsson UE, Sundgren M,
Svenheden A, et al. Absorption, gastrointestinal transit, and tablet
erosion of felodipine extended-release (ER) tablets. Pharm Res
Wise DI. Hand book of pharmaceutical controlled release technology.
st ed. Marcel Dekkar; 2005. p. 211-53.
Streobel A, Siepmann J, Bodmeier R. Expert opinion on drug delivery.
rd ed.; 2006. p. 217-33.
Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a
novel controlled-release system for gastric retention. Pharm Res
Ponchel G, Irache J. Specific and non-specific bioadhesive particulate
systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv
Davis SS, Stockwell A, Taylor MJ. Pharm Res 1986;3:208-13.
Urguhart J, Theeuwes F. Drug delivery system comprising a reservoir
containing a plurality of tiny pills. US patent 1994;4:434,153.
Kedzierewicz F, Thouvenot P, Lemut J, Etinine A, Hoffonan M, Maincent
P. Evaluation of peroral silicone dosage forms in humans by gamma-
scintigraphy. J Control Release 1999;58:195-205.
Jain SK, Agarval GP, Jain NK. Evaluation of porous carrier-based
floating orlistat microspheres for gastric delivery. AAPS PharmSciTech
Gambhier MN, Ambade KW, Kurmi SD, Kadam VJ, Jadhav KR.
Development and in vitro evaluation of an oral floating matrix
tablet formulation of diltiazem hydrochloride. AAPS PharmSciTech
McTavish D, Sorkin EM. Verapamil. An updated review of its
pharmacodynamic and pharmacokinetic properties, and therapeutic
use in hypertension. Drugs 1989;38:19-76.
Reynolds JE. In: Martindale, editor. The Extra Pharmacopoeia. 3rd ed.
London: The Pharmaceutical Press; 1996. p. 961-3.
Goodman, Gilmans. The pharmacological basis of therapeutics. 11th ed.
Baumgartner S, Kristl J, Vrecer F, Vodopivee P, Zorko B. Optimisation of floating matrix tablets and evaluation of their gastric residence time.
Int J Pharm 2000;195:125-35.
Vyas SP, Roop KK. Controlled Drug Delivery Concepts and Advances.
Wells J, Aulton ME, Pharmaceutics: The Science of Dosage Form
Design. 3rd ed. Melbourne and New York: Edinburgh London; 1998.
Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for
floating drug delivery system: Effects of CO (2) gas-forming agents. Int
J Pharm 2002;239:81-91.
Indian Pharmacopoeia. Govt. of India, Ministry of Health and Family
Welfare. Vol. 2. Delhi: The Controller of Publication; 1996. p. 796-7,
Atyabi F, Sharma HL, Hah M, Fell Jt. In vivo evaluation of a novel
gastroretentive formulation based on ion exchange resins. J Control